Provided by Tiger Trade Technology Pte. Ltd.

Actinium Pharmaceuticals

1.03
-0.0200-1.90%
Post-market: 1.050.0200+1.94%19:32 EDT
Volume:54.23K
Turnover:55.95K
Market Cap:32.32M
PE:2.89
High:1.06
Open:1.05
Low:1.02
Close:1.05
52wk High:1.74
52wk Low:0.7351
Shares:31.37M
Float Shares:31.25M
Volume Ratio:0.81
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3559
EPS(LYR):-1.0900
ROE:45.86%
ROA:11.58%
PB:1.07
PE(LYR):-0.94

Loading ...

Actinium gets NYSE American notice for failing $4 million stockholders’ equity listing standard

Reuters
·
May 30

Actinium Pharmaceuticals presents new preclinical ATNM-400 data in prostate cancer, NSCLC at SNMMI 2026

Reuters
·
May 30

Actinium Pharma Q1 FY26 net loss narrows to $5.5 million; no revenue

Reuters
·
May 09

Actinium Pharmaceuticals to present SNMMI 2026 preclinical data on ATNM-400 radioconjugate

Reuters
·
May 06

Actinium Pharmaceuticals Announces Three Snmmi 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

THOMSON REUTERS
·
May 06

Reinforced Buy on Actinium: Strengthening ATNM-400 Pan-Tumor Data and Expanding Actimab-A AML Opportunities Drive Pipeline Upside

TIPRANKS
·
Apr 23

Actinium reports AACR preclinical pan-tumor efficacy data for Ac-225 radiotherapy ATNM-400

Reuters
·
Apr 22

Actinium Pharmaceuticals Inc - Atnm-400 Well Tolerated With No in Vivo Toxicities Observed at Efficacious Doses

THOMSON REUTERS
·
Apr 22

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for Atnm-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

THOMSON REUTERS
·
Apr 22

Actinium Pharmaceuticals Inc - Atnm-400 Demonstrates Pan-Tumor Activity Across Prostate, Lung, and Breast Cancer Models

THOMSON REUTERS
·
Apr 22

Actinium Pharmaceuticals Inc - Atnm-400 Shows Efficacy in High and Low Psma-Expressing Prostate Cancer Models

THOMSON REUTERS
·
Apr 22

Actinium Pharmaceuticals: Undervalued Radiopharmaceutical Play with Promising ATNM-400 Pipeline and Near‑Term Catalysts

TIPRANKS
·
Apr 09

Actinium to present new ATNM-400 solid tumor preclinical data at AACR 2026

Reuters
·
Apr 06

Analysts Are Bullish on Top Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Actinium Pharmaceuticals (ATNM)

TIPRANKS
·
Apr 03

Actinium Pharmaceuticals Price Target Maintained With a $5.00/Share by Stephens & Co.

Dow Jones
·
Mar 31

Actinium Pharmaceuticals (ATNM) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Mar 31

Actinium net loss narrows to $33.9 million in FY25

Reuters
·
Mar 31

Actinium Pharmaceuticals files 8-K/A; board sets annual say-on-pay votes due to March 20, 2026 decision

Reuters
·
Mar 27